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Abstract 
 
Children with cancer are potentially at high risk of plasma 25-hydroxyvitamin D [25(OH)D] 
inadequacy and despite UK vitamin D supplementation guidelines their implementation remains 
inconsistent. Thus, we aimed to investigate 25(OH)D concentration and factors contributing to 
25(OH)D inadequacy in paediatric cancer patients. A prospective cohort study of Scottish 
children aged <18 years, diagnosed with and treated for cancer (patients) between Aug 2010-Jan 
2014 was performed, with control data from Scottish healthy children (controls). Clinical and 
nutritional data were collected at defined periods up to 24 months. 25(OH)D status was defined 
by the Royal College of Paediatrics and Child Health (2013); inadequacy [<50 nmol/L: 
deficiency (<25 nmol/L), insufficiency (25-50 nmol/L)], sufficiency (51-75 nmol/L), optimal 
(>75 nmol/L). Eighty-two patients [median(IQR) age 3.9(1.9-8.8); 56% males)] and 35 controls 
[median(IQR) age (6.2(4.8-9.1); 49% males] were recruited. 25(OH)D inadequacy was highly 
prevalent in the controls (63%; 22/35), and in the patients (64%; 42/65) at both baseline and 
during treatment (33-50%). Non-supplemented children had the highest prevalence of 25(OH)D 
inadequacy at every stage with 25(OH)D median(IQR) ranging from 32.0 (21.0-46.5) nmol/L to 
45.0(28.0-64.5) nmol/L. Older age at baseline [R=-0.46; p<0.001], overnutrition (BMI ≥85th 
centile) at 3 months [p=0.005; RR=3.1] and not being supplemented at 6 months (p=0.04; 
RR=4.3) may have contributed to lower plasma 25(OH)D. Paediatric cancer patients are not at 
higher risk of 25(OH)D inadequacy than healthy children at diagnosis; however prevalence of 
25(OH)D inadequacy is still high and non-supplemented children have a higher risk. Appropriate 
monitoring and therapeutic supplementation should be implemented.        
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INTRODUCTION  1 
Plasma 25-hydroxyvitamin D (25(OH)D) inadequacy (<50 nmol/L; deficiency and insufficiency) 2 
is a recognised health problem
(1)
. Despite vitamin D supplementation guidelines
(2,3)
, their 3 
implementation remains inconsistent
(4)
 and 25(OH)D inadequacy in healthy children ranges from 4 
14% to 49% worldwide
(5)
. A recent systematic review reported prevalence of plasma 25(OH)D 5 
deficiency and insufficiency of 41% and 59% respectively in European paediatric cancer 6 
patients, higher than healthy children and paediatric cancer patients from North America (15% 7 
and 46%) and the Middle East (24% and 51%)
(6)
. 8 
Plasma 25(OH)D is primarily obtained from UVB sunlight through dermal synthesis, but it can 9 
also be obtained from the diet. However few foods naturally contain vitamin D
(7)
, and in the UK 10 
fortification is rare
(8)
. In high latitude countries, like Scotland
(8)
, populations are at an increased 11 
risk of 25(OH)D inadequacy. Other factors contributing to 25(OH)D inadequacy in children have 12 
been attributed to skin pigmentation, obesity and age (infants and adolescents)
(2,7)
. 13 
Children treated for cancer experience multiple side-effects, which might affect plasma 14 
25(OH)D. These include phototoxicity, which requires avoidance of direct sunlight, reduced 15 
dietary intake
(9)
, hepatotoxicity and nephrotoxicity, which may interfere with the activation of 16 
25(OH)D
(10)
. 25(OH)D inadequacy in children increases risk of bone fractures, rickets and slow 17 
growth
(11)
, with a subsequent increased risk of osteoporosis 
(12)
. Most children and adolescents 18 
treated for cancer survive into adulthood
(13)
, but have an increased risk of developing metabolic 19 
syndrome, cardiac complications and have a reduced peak bone mass
(13)
. Despite the importance 20 
of vitamin D to health, the high prevalence of 25(OH)D inadequacy in Europe and the recent call 21 
for high-quality population-based longitudinal cohort studies, there are few published studies in 22 
the UK and none in Scotland, investigating plasma 25(OH)D concentration in paediatric cancer 23 
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patients
(6)
. To address this clinical question we aimed to: investigate both plasma 25(OH)D and 24 
parathyroid hormone (PTH) concentration of paediatric cancer patients at defined time points for 25 
24 months; compare plasma 25(OH)D concentration of healthy children with a paediatric cancer 26 
cohort from Scotland and explore possible factors (age, ethnicity, gender, seasonality, nutritional 27 
status, diagnosis, treatment and the use of nutritional support) contributing to plasma 25(OH)D 28 
inadequacy at baseline and at 3 and 6 months. 29 
METHODS 30 
Study design, population and time-line 31 
A prospective cohort study was performed. Eligibility criteria were: children aged <18 years; 32 
diagnosed with cancer (ICCC-3)
(14)
  or Langerhans Cell Histiocytosis between Aug-2010 and 33 
Jan-2014; attending the South East Scotland regional centre (56ºN) for Haematology and 34 
Oncology at the Royal Hospital for Sick Children (RHSC), Edinburgh or Ninewells Hospital, 35 
Dundee and patients were recruited consecutively. We excluded children who were treated 36 
palliatively at any time. Children were monitored for a maximum period of 24 months and all 37 
measurements were obtained at baseline (newly diagnosed), 3, 6, 9 and 12 months and every 6 38 
months thereafter. Factors contributing to plasma 25(OH)D inadequacy were only explored at 39 
baseline and at 3 and 6 months due to the reduced sample size at later stages.   40 
Anonymised control data were obtained from the control subjects recruited within a case-control 41 
study of Vitamin D in children with epilepsy carried out between July 2013 and March 2014 at 42 
RHSC. Controls were recruited over an overlapping time frame, similar representative seasons 43 
and regions as the cancer patients. Consecutive potentially eligible controls attending the RHSC 44 
Emergency Department (which serves SE Scotland) who were previously healthy, not in 45 
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extremis nor had an existing chronic condition (and specifically no epilepsy or other seizure 46 
disorder) and who required blood samples to be taken as part of their clinical assessment (eg 47 
child with a fever), were invited to the epilepsy study. Participants to the epilepsy study along 48 
with their parents gave written informed consent and where appropriate – informed assent. 49 
Recruitment was completed when the target sample size for each season was achieved. Advice 50 
on vitamin D supplementation was not provided prior to sample collection.  Ethical approval for 51 
secondary use of the anonymised control data for comparison to that of the cancer patients in this 52 
study, without the need for additional consent, was given by the South East Scotland Research 53 
Ethics Service.  Control data were not matched for age, sex or BMI; however samples were 54 
matched for synthesising (1st of April-30th Sep) and non-synthesising periods (1st Oct-31st Mar)  55 
for comparative reasons.  56 
Demographics and clinical parameters 57 
Clinical data (diagnosis, treatment protocol and length of treatment) and demographic data (age, 58 
gender, ethnicity and socioeconomic deprivation) were collected from medical notes. Treatment 59 
intensity was classified according to Kazak et al.
(15)
 As a proxy marker for socioeconomic 60 
deprivation of individuals, we used Standard Index of Multiple Deprivation (SIMD).(16)   61 
The paediatric cancer cohort was grouped according to the wider definition of solid tumours, 62 
haematological cancers, brain tumours and other associated diagnoses. 63 
Data collection  64 
Plasma 25(OH)D, parathyroid hormone (PTH), calcium, phosphate and magnesium 65 
concentrations were measured. Plasma 25(OH)D was analysed using Liquid Chromatography-66 
Tandem Mass Spectrometry (LC-MS/MS) technique at the Royal Infirmary of Glasgow and PTH 67 
was analysed using the Immulite 2000 Intact PTH technique at the Royal Infirmary of 68 
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Edinburgh.  The immediate coefficient of variation (%) for the assays were ≤8.9% and 5.7% 69 
respectively.  Calcium, phosphate and magnesium were analysed using the Abbott Architect 70 
c8000 at RHSC  71 
Plasma 25(OH)D concentration was classified as synthesising (1st of April-30th Sep) and non-72 
synthesising periods (1st Oct-31st Mar). Plasma 25(OH)D was defined according to the Royal 73 
College of Paediatrics and Child Health (2013)(2); deficiency (<25 nmol/L), insufficiency (25-50 74 
nmol/L), sufficiency (51-75 nmol/L), optimal (>75 nmol/L). Plasma 25(OH)D inadequacy was 75 
used when 25(OH)D concentration was <50 nmol/L. Plasma 25(OH)D toxicity was defined as 76 
>175 nmol/L (with associated symptoms) and the PTH reference as 1.7-7.5pmol/L
(17)
.  77 
Height (or length) and weight were measured using standard procedures. Body mass index 78 
(BMI) centile was calculated and UK BMI growth centiles were used. Nutritional status was 79 
classified as underweight (BMI ≤2.3th centile), healthy weight (BMI >2.3rd to <85th centile) and 80 
overweight (BMI ≥85th centile)(18). Vitamin D intake was assessed using a 24 hour multi-pass 81 
recall method
(19)
 to establish patterns of change in vitamin D throughout the study period. This 82 
was analysed in WinDiets® (Univation Ltd 2005) programme
(20)
. Any nutritional treatment and 83 
vitamin D supplementation was recorded. Nutritional treatment was prescribed according to 84 
Subjective Global assessment by the multidisciplinary team and consisted of enteral +/- 85 
parenteral nutrition (macronutrient) and micronutrient (vitamin D according to UK RCPCH 86 
guidelines
(2)
 or multivitamins), and a combination of macronutrients and micronutrients.  87 
This study was granted ethical approval from NHS Scotland (NHS REC 06-51104-52). 88 
Statistical analyses 89 
The Statistical Package for Social Science (IBM-SPSS for Windows Statistics, version 19) was 90 
employed to analyse all data. Descriptive statistics were used to evaluate the prevalence of 91 
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plasma 25(OH)D inadequacy. Comparisons between the paediatric cancer cohort and the healthy 92 
controls were performed using Mann-Whitney; correlations between plasma 25(OH)D and the 93 
following variables: calcium, PTH, BMI centile and age, were performed using Spearman’s 94 
correlation. Univariate associations between demographic data and categorical variables were 95 
established by χ2-test. P <0.05 was considered statistically significant. We followed the 96 
STROBE guidelines for the presentation of our data
(21)
. No a priori sample size estimation was 97 
performed for this pilot study in a regional cohort of paediatric cancer patients. 98 
RESULTS  99 
Demographic and clinical characteristics  100 
Thirty-three of 35 healthy controls and 65 of 82 paediatric cancer patients had plasma 25(OH)D 101 
samples available at baseline (figure 1). Of the healthy controls, two (6%) samples were never 102 
returned due to laboratory issues. Demographic and clinical characteristics of the population are 103 
presented in table I and II. Gender, ethnicity and socioeconomic status as well as age at diagnosis 104 
did not statistically differ between groups. BMI centiles were significantly lower in the paediatric 105 
cancer cohort. Twenty-four treatment protocols were used to treat the paediatric cancer cohort, 106 
the median (IQR) time follow up was 312 (123.5-653.2) days and 22% (n=18) were classified as 107 
low risk, 37% (n=30) as medium risk and 41.5% (n=34) as high risk. The time between diagnosis 108 
and baseline measurements was 15.5 (10.0-25.0) days and between the start of cancer treatment 109 
and baseline measurements was 9.5 (6.0-19.5) days. All patients were receiving cancer treatment 110 
when plasma 25(OH)D samples were taken.  111 
Plasma 25(OH)D concentration 112 
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At baseline, of the 82 paediatric cancer patients, 17 (21%) did not have plasma 25(OH)D 113 
available due to clinical reasons (figure 1), 34 (41%) were obtained during the synthesising 114 
period and 31 (38%) during non-synthesising period. There was no difference [U (453); p=0.3] 115 
between the synthesising (median 39.0, IQR 30.0-62.0) and non-synthesising period (median 36, 116 
IQR 16.0-61.0) in plasma 25(OH)D concentration in the cancer cohort at any time-point, apart 117 
from the 3 month follow up (figure 2). Of the 35 controls, 19 (54%) were obtained during the 118 
synthesising period and 12 (34%) during the non-synthesising period. Plasma 25(OH)D (nmol/L)  119 
statistically differed [U (42.5); p=0.003)] during the non-synthesising (median 26.0, IQR 18.0-120 
46.5) and synthesising period (median 56.5, IQR 45.5-78.0) . Baseline plasma 25(OH)D of the 121 
cancer cohort did not differ from the healthy controls (p=0.7).         122 
At baseline, prevalence of plasma 25(OH)D inadequacy was 64% (42/65) in cancer patients and 123 
63% (22/35) in healthy children. There was a higher prevalence of plasma 25(OH)D deficiency 124 
in paediatric cancer patients (n=19; 29%) in comparison with healthy children (n=8; 22%) but 125 
this was not statistically significant (p=0.2; χ2-test). In the cancer cohort, prevalence of plasma 126 
25(OH)D inadequacy ranged between 33-50% throughout the study period (figure 3). Patients 127 
with solid tumours had the highest prevalence of 25(OH)D inadequacy (34%) followed by 128 
haematological malignancies (26%) at both baseline (table II) and at all time-points 129 
(supplemental table I). At baseline, of 32 solid tumour patients 37.5% (n=12) were deficient and 130 
31.2% (n=10) were insufficient and of 26 haemalogical malignancy patients 19.2% (n=5) were 131 
deficient and 46.1% (n=12) were insufficient (table II).    132 
Nutritional support was prescribed to 26% (21/82) of paediatric cancer patients at baseline of 133 
which, 14/82 (17%) were on macronutrient (enteral +/- parenteral nutrition), and 7/82 (8%) were 134 
on both macronutrient (enteral+/- parenteral nutrition) and micronutrient. The median (IQR) time 135 
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between the start of nutritional support and baseline was 8 (0-23) days. Eighty percent (66/82) of 136 
cancer patients received vitamin D from one or more forms of nutritional support for several 137 
days or weeks during the study period. Of these, 39/82 received macronutrient supplementation 138 
providing 292 (128-332)IU per day, 48/82 (58%) received both micronutrient and macronutrient 139 
supplementation providing 464 (440-664)IU per day and 21/82 (26%) received macronutrient 140 
only and micronutrient (+/- macronutrient) supplementation. The vitamin D intake from diet 141 
alone was 68 (24-76)IU per day and supplementation of vitamin D ranged from 400IU per day to 142 
20,000 IU single dose of vitamin D during the study period.   143 
Paediatric cancer patients who were not supplemented had the lowest plasma 25(OH)D. The 144 
prevalence of plasma 25(OH)D inadequacy stratified by nutritional support and stages of disease 145 
is presented in table III. This was highest in children who did not receive supplementation 146 
ranging from 32.0 (21.0-46.5) nmol/L at 18 months to 45.0 (28.0-64.5) nmol/L at 24 months. In 147 
contrast, paediatric cancer patients supplemented with micronutrient (+/- macronutrient) had the 148 
lowest prevalence of plasma 25(OH)D inadequacy and the highest plasma 25(OH)D at most 149 
stages ranging from 63.0 (42.7-128.5) nmol/L at 6 months to 82.0 (57.0-128.5) nmol/L at 12 150 
months. This was followed by children supplemented with macronutrient only, which ranged 151 
from 43.0 (29.2-75.7) nmol/L at baseline to 79.0 (49.0-93.0) nmol/L at 6 months. A considerable 152 
number of patients in the macronutrient subgroup had already received micronutrient 153 
supplementation. Of the 7 patients who were on macronutrient support at 6 months, all of them 154 
had received micronutrient supplementation previously. Likewise, 2/5 (40%) patients on 155 
macronutrient support at 12 months and 1/2 (50%) patients at 18 months had received 156 
micronutrient supplementation in the previous follow up. Moreover, micronutrient 157 
supplementation was significantly associated with lower prevalence of plasma 25(OH)D 158 
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inadequacy (Fisher’s Exact test; p=0.04; RR 0.27; 95% CI 0.04-1.8) at 6 months. Three patients 159 
reached plasma 25(OH)D concentration of >175nmol/L(17) following a single high dose (20,000 160 
IU/day) of vitamin D.       161 
Plasma 25(OH)D did not correlate with plasma calcium, phosphate, magnesium and PTH at any 162 
stage in the cancer cohort, however PTH and plasma 25(OH)D concentration correlated in the 163 
healthy controls [r=0.6; p<0.001].  164 
Factors contributing to 25(OH)D inadequacy concentration at baseline and at 3 and 6 165 
months of treatment  166 
Age negatively correlated with plasma 25(OH)D concentration in paediatric cancer patients [r=-167 
0.46; p<0.001], only at baseline, and in healthy children [r=-0.42; p<0.02], whereby older 168 
children had lower plasma 25(OH)D concentration. Although, BMI centile was not significantly 169 
correlated with plasma 25(OH)D concentration in the paediatric cancer cohort at baseline [r=-170 
0.2; p=0.08], 3 months [r=-0.2; p=0.2] and 6 months [r=-0.2; p=0.3], and in the healthy control 171 
[r=-0.3; p=0.3], overnourished paediatric cancer patients were more likely to have higher 172 
prevalence of plasma 25(OH)D inadequacy [χ2-test(8.3); df(1); p=0.005; RR 3.1; 95% CI 1.4-173 
14.0] at 3 months than healthy and undernourished children with cancer, regardless of whether 174 
the patients were on nutritional supplementation. Non-supplemented children were more likely to 175 
have inadequate plasma 25(OH)D concentration (RR 4.3; 95% CI 1.1-4.7) at 6 months (Fisher’s 176 
Exact test; p=0.04) compared with those supplemented with micronutrients.    177 
None of the following categorical variables were significantly associated with plasma 25(OH)D 178 
status and paediatric cancer patients at any stage; treatment risk, diagnostic criteria, ethnicity and 179 
gender.     180 
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DISCUSSION  181 
This is the first study investigating plasma 25(OH)D concentration at diagnosis and during 182 
treatment in paediatric cancer patients from Scotland. Our results show a high prevalence of 183 
plasma 25(OH)D inadequacy during the study period. Plasma 25(OH)D concentration in 184 
paediatric cancer patients and age matched healthy controls were similar;  however, our 185 
paediatric cancer cohort showed no seasonal variation. Children diagnosed with solid tumours 186 
exhibited the lowest plasma 25(OH)D concentration and the only effective method to achieve 187 
optimal plasma 25(OH)D concentration was by supplementing with vitamin D. Only 3 factors, 188 
and each at 1 time point only, contributed to plasma 25(OH)D inadequacy; older age was the 189 
only factor at baseline, overnutrition at 3 months and not being supplemented at 6 months during 190 
treatment. 191 
Prevalence of plasma 25(OH)D  192 
In contrast to North England(22) but in agreement with a recent Scottish small study 
(24)
, our study 193 
shows that plasma 25(OH)D concentration in newly diagnosed paediatric cancer patients and 194 
healthy children were comparable suggesting that patients from Scotland are not at higher risk of 195 
plasma 25(OH)D inadequacy than healthy children at diagnosis. However, these concentrations 196 
are lower than those reported in paediatric cancer patients from Europe
(6). Of note, 11% of 197 
paediatric cancer patients were on vitamin D supplementation at baseline, which may have 198 
contributed to higher plasma 25(OH)D concentration at this stage. Additionally, there was a 199 
higher representation of winter samples in the healthy controls than the paediatric cancer cohort 200 
(30% v 43%), which might have contributed to the unexpectedly higher prevalence of vitamin D 201 
inadequacy in the healthy controls.   202 
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Optimal plasma 25(OH)D in children is essential to allow optimal growth, calcium homeostasis 203 
and skeletal development(3). Children treated for cancer may have impaired growth velocity 204 
during treatment(27
)
, which can also be exacerbated by vitamin D inadequacy. Current UK 205 
guidelines on vitamin D are aimed at healthy children and stipulate that children under 5 years 206 
old should be supplemented with 7.5-10µg/day (300-400 IU) of vitamin D
(2). We have clearly 207 
established that most cancer patients who were not supplemented were either deficient or 208 
insufficient, or eventually became deficient as shown by the high prevalence of plasma 25(OH)D 209 
inadequacy (33-50%). Furthermore, macronutrient supplementation alone prevented plasma 210 
25(OH)D inadequacy, but patients rarely reached optimal concentration, suggesting that 211 
macronutrient supplementation, which is fortified with vitamin D, does not meet the 212 
requirements for vitamin D in this population. Finally, vitamin D supplementation taken in the 213 
form of multivitamins or as therapeutic supplementation was essential to achieve optimal 214 
25(OH)D concentration in all paediatric cancer patients. Remarkably, we found that older 215 
children were at higher risk of plasma 25(OH)D inadequacy at baseline and therefore would also 216 
require supplementation, which is not stipulated in the RCPCH (2013) guidelines(2
)
. However, it 217 
is important to note that three patients on single high dose (20,000 IU) vitamin D 218 
supplementation reached 25(OH)D >175 nmol/L concentration(17). Therefore, we recommend 219 
vitamin D supplementation for all paediatric cancer patients, but emphasise the need for close 220 
monitoring to avoid potential toxicity.        221 
Unlike healthy children, our paediatric cancer cohort did not show any seasonal variation in 222 
plasma 25(OH)D concentration. These findings are supported by a study performed in survivors 223 
of childhood cancer from the USA (latitude 34ºN)(26) but contrasts with two studies(22,25); one 224 
performed in North England (latitude 54.9ºN) during and after therapy(22) and the other 225 
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performed in Israel (latitude 31ºN) in paediatric cancer patients during therapy(25
)
.  Therefore, we 226 
hypothesise that Scottish paediatric cancer patients are not exposed to enough sunlight during the 227 
summer months, probably due to the multiple treatment side-effects(26,27
)
, and that diet alone is 228 
insufficient to replenish plasma 25(OH)D stores.        229 
Stratification of the data by diagnosis revealed results consistent with a recent systematic 230 
review(6
)
 and a large study (n=2198) performed in the adult oncology population from USA. 231 
Patients diagnosed with solid tumours had prevalence of plasma 25(OH)D inadequacy of 71% 232 
and 75% respectively, our study showed that children diagnosed with solid tumours exhibited the 233 
highest prevalence of plasma 25(OH)D inadequacy (69%; deficiency 37.5% and insufficiency 234 
31.2%) at diagnosis. However, our study also showed high prevalence of plasma 25(OH)D 235 
inadequacy in the haematological malignancy group (65%; deficiency 19.2% and insufficiency 236 
46.1%) at diagnosis, which contrasts with findings from elsewhere(6,26
)
. Although others have 237 
reported similar prevalence of vitamin D inadequacy in Canadian children diagnosed with 238 
haematological malignancies(29,30
)
, the measured vitamin D was 1,25-dihydroxyvitamin D 239 
(1,25(OH)2D), which is not equivalent to plasma 25(OH)D. Despite supplementation with 240 
macronutrients and micronutrients, prevalence of 25(OH)D inadequacy remained high during 241 
treatment for solid tumours and haematological malignancies highlighting the need for more 242 
rigorous monitoring at all stages.        243 
In line with recent evidence(6,22
)
, our study found a relationship between PTH and plasma 244 
25(OH)D in healthy controls, but not in paediatric cancer patients. Although, in health PTH 245 
measured alongside plasma 25(OH)D is considered the most sensitive physiological measure of 246 
plasma 25(OH)D status and bone homeostasis(31), our study suggests that there might be other 247 
factors influencing their relationship. We were unable to investigate this due to the relatively 248 
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small sample; however it has been attributed to the type of cancer and the different treatments, 249 
including chemotherapy and corticosteroids, which can lead to nephrotoxicity and 250 
hepatotoxicity, in turn interfering with the 25(OH)D, 1,25(OH)2D and PTH metabolism
(10,32). 251 
Furthermore, a stronger relationship between plasma PTH and 25(OH)D develops with age(33
)
 252 
which might have affected our results, since the controls were slightly older.           253 
Factors contributing to reduced plasma 25(OH)D concentration at baseline and at 3 and 6 254 
months         255 
Consistent with a meta-analysis
(6)
, older age was associated with reduced plasma 25(OH)D 256 
concentration in paediatric cancer patients at baseline. This association was also found in our 257 
healthy controls, in line with a study performed in healthy children from the USA
(34)
, which 258 
could reflect the widespread issue of vitamin D. Teenagers tend to eat less vitamin D rich foods, 259 
especially fortified foods, and spend less time playing outdoors than younger children
(24)
. 260 
Additionally, the high levels of vitamin D inadequacy during treatment could have been 261 
attributed to the fact that patients were supplemented with a very low dose of vitamin D (440-262 
664 IU). A higher dose of 600IU is recommended for all paediatric patients (including infants), 263 
whilst therapeutic doses are age dependent and all doses are over 1000IU per day
(3,17)
. Alongside 264 
infancy, puberty is accompanied by a rapid period of growth and appropriate plasma 25(OH)D 265 
concentration are essential to allow for optimal growth
(35)
; thus this population should be 266 
targeted and appropriate doses should be prescribed to all patients.  267 
Like healthy individuals
(7)
, but contrary to other studies investigating factors contributing to 268 
plasma 25(OH)D inadequacy in paediatric cancer patients
(24,25)
, our results showed that 269 
overnourished children maybe more likely to have plasma 25(OH)D inadequacy following 3 270 
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months of treatment and this was regardless of nutritional support. An inverse relationship 271 
between high BMI and plasma 25(OH)D in the healthy population is well established
(7)
, which 272 
has been attributed to a reduction in plasma 25(OH)D availability due to the sequestration of 273 
vitamin D by adipose tissue
(36)
. Overweight children require higher doses of chemotherapy and 274 
glucocorticoids than normal weight or undernourished children. Additionally, cancer treatments 275 
tend to be most intense during the first 3 to 6 months post-diagnosis. Chemotherapy agents 276 
commonly used in cancer treatment can cause hepatotoxicity and nephrotoxicity and thus inhibit 277 
the activation of vitamin D
(29)
. Whilst glucocorticoids stimulate vitamin D catabolism and can 278 
increase the risk of vitamin D deficiency 
(29)
. Therefore, higher doses of chemotherapy agents 279 
and glucocorticoids may explain this association between overnourished patients and lower 280 
25(OH)D concentration 281 
Limitations of the study and future research  282 
The reduced sample size at later stages of the study precluded considering factors associated with 283 
plasma 25(OH)D at later stages of treatment. Some cancer patients were already on nutritional 284 
support at baseline, which could potentially have affected plasma 25(OH)D concentration. It 285 
should be noted that although age did not statistically differ between the controls and the cancer 286 
cohort, the controls were slightly older. Also, the higher proportion of samples obtained from the 287 
non-synthesising period in the controls may have distorted the high plasma 25(OH)D inadequacy 288 
reported. Finally, there were only 2 non-Caucasian patients (dark skin) in both groups, which 289 
could explain why lower plasma 25(OH)D concentration was not associated with ethnicity. 290 
Future research should include large multicentre epidemiological studies that are better able to 291 
identify factors contributing to plasma 25(OH)D inadequacy in the different types of cancer 292 
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during treatment. Also, randomised controls trials in which the effects of vitamin D 293 
supplementation on clinical outcome, particularly bone mass density, are warranted.     294 
CONCLUSION  295 
We have highlighted that Scottish paediatric cancer patients have a high prevalence of plasma 296 
25(OH)D inadequacy at diagnosis and during treatment and that older age, not being 297 
supplemented and possibly being overnourished potentially contributes to inadequacy. 298 
Importantly, we recommend vitamin D supplementation to all paediatric cancer patients given 299 
that macronutrient supplementation alone prevented further 25(OH)D inadequacy, but rarely 300 
produced optimal concentration, and high longitudinal inadequacy rates continued throughout 301 
the study. 302 
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Tables 
Table I. Characteristics of the paediatric cancer population and the healthy controls.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; CML: chronic myeloid 
leukaemia; HLH: haemophagocytic lymphohistiocytosis; LCH: Langerhan’s Cell Histiocytosis; 
CNS: central nervous system; 
1
Mann-Whitney test; 
2
chi square-test. SIMD: Standard Index of 
Multiple Deprivation presented as a quintile where “I” denotes the most deprived and “V” the 
least deprived.   
Baseline characteristics Paediatric cancer 
cohort 
Controls P 
value 
Total sample (n) 82 35  
Age median (IQR) 3.9 (1.9-8.8) 6.2 (4.8-9.1) 0.1
1 
BMI centile median (IQR) 50 (19.0-84.5) 60.5 (43.7-89.5) 0.003
1 
Plasma 25(OH)D median (IQR) 38.0 (21.0-61.0) 37.5 (23.0-58.0) 0.7
1 
 n % n %  
Gender      0.5
2 
   male  46 56.1 17 48.6  
   female 36 43.9 18 51.4  
Ethnicity      0.6
2 
   White  80 97.6 33 94.3  
   Non-white 2 2.4 2 5.7  
SES     0.06
2 
   I 15 18.3 3 8.6  
   II 13 15.8 8 22.9  
   III 15 18.3 5 14.3  
   IV 24 29.3 5 14.3  
   V 15 18.3 14 40.0  
Haematological malignancies 35 43 - - 
 
   ALL 29 35    
   AML 3 4    
   CML  2 2    
   HLH 1 1    
Solid tumours 39 47    
  Lymphomas 10 12    
  Neuroblastoma 6 7 - -  
  Retinoblastoma 2 2 - -  
  Renal tumours  6 7 - -  
  Hepatic tumours 1 1 - -  
  Malignant bone tumours 4 5 - -  
  Soft tissue sarcoma 5 6 - -  
  Germ cell tumours 1 1 - -  
  Malignant epithelial neoplasm  4 5 - -  
  Others unspecified malignancy 0 0 - -  
Other associated diagnoses 3 4 - -  
   LCH 3 4    
Brain tumours-CNS tumours 5 6    
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Table II. Plasma 25(OH)D concentration of the paediatric cancer cohort and the healthy controls at baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ST: Solid tumours; HM: Haematological malignancies; BT: Brain tumours; OAD: other associated-diagnoses; 
1χ2-test; 2Fisher’s Exact 
test; 25(OH)D reference ranges: Deficiency: <25 nmol/L; Insufficiency: 25-50 nmol/L; sufficiency: 51-75 nmol/L; optimal: >75 
nmol/L; 25(OH)D inadequacy (<50 nmol/L).   
 
 
 
 
  
N Median (IQR) Deficient 
N (%) 
Insufficient 
N (%) 
Sufficiency 
N (%) 
Optimal  
N (%) 
P 
value 
co
n
tr
o
ls
 
  
 
n=35 
 
37.5 
 (23.0-58.0) 
 
8 (22.8) 
 
14 (40.0) 
 
6 (17.1%) 
 
5 (14.3) 
 
0.06
1 
P
a
ed
ia
tr
ic
 c
a
n
ce
r 
C
a
se
s  
n=65 
 
38.0  
(21.0-61.0) 
 
19 (29.2) 
 
23 (35.4) 
 
16 (24.6) 
 
7 (10.8) 
0.01
1 
D
ia
g
n
o
st
ic
 g
ro
u
p
 ST n=32 35.0  
(16.0-60.0) 
12 (37.5) 10 (31.2) 8 (25.0) 2 (6.25) 0.02
1 
HM n=26 38.0  
(27.7-52.2) 
5 (19.2) 12 (46.1) 6 (23.1) 3 (11.5) 0.04
1 
BT n=5 69  
(14.5-75.5) 
2 (40.0) 0 2 (40.0) 1 (20.0) - 
OAD n=2 80 0 0 1 (50.0) 1 (50.0) - 
N
u
tr
it
io
n
 
S
u
p
p
o
rt
 
None n=44 34.0(20.2-52.7) 16 (36.4) 15 (34.1) 11 (25.0) 3 (6.9) 0.006
1 
Macronutrients 
n=14 
43.0(29.2-75.7) 2 (14.3) 6 (42.8) 3 (21.4) 3 (21.4) 0.8
2 
Micronutrients 
n=7 
71.0(41.0-97.0) 1 (14.3) 1 (14.3) 3 (42.9) 2 (28.6) 0.9
2 
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Table III. Prevalence of plasma 25(OH)D inadequacy with data stratified by nutritional support 
and at different stages of the disease  
1
OAD: other associated diagnoses; 25(OH)D reference ranges: Deficiency: <25 nmol/L; 
Insufficiency: 25-50 nmol/L; sufficiency: 51-75 nmol/L; optimal: >75 nmol/L; 25(OH)D 
inadequacy (<50 nmol/L) 
 
 
 
 
Time 
line  
Nutritional 
support 
 Deficiency  Insufficiency  Sufficiency  
 
Optimal  
 
Median (IQR) 
  N N  % N % N % N %  
Baseline None 44 16 25 15 23 11 17 2 3 34.0(20.2-52.7) 
N=65 Macronutrients 14 2 3 6 9 3 5 3 5 43.0(29.2-75.7) 
 Micronutrients+/- 
macronutrients 
7 1 1 1 1 3 5 2  3 71.0(41.0-97.0) 
3 
months 
None 25 4 7 11 20 6 11 4 7 45.0(32.0-56.0) 
N=55 Macronutrients 9 1 2 1 2 4 7 3 5 67.0(48.0-76.5) 
 Micronutrients+/- 
macronutrients
* 
20 1 2 6 11 7 13 6 11 67.5(38.0-87.7) 
6 
months 
None 9 3 9 2 6 4 12 0 0 45.0(16.5-68.0) 
N=34 Macronutrients 7 0 0 2 6 1 3 4 12 79.0(49.0-93.0) 
 Micronutrients+/- 
macronutrients 
18 1 3 3 9 4 12 10 29 78.0(49.2-134.5) 
9 
months 
None 16 1 3 7 23 6 20 2 7 45.0(31.0-61.0) 
N=30 Macronutrients 8 1 3 2 7 2 7 3 10 59.0(35.5-84.25) 
 Micronutrients+/- 
macronutrients 
6 0 0 0  2 7 4 13 77.5(66.5-101.0) 
12 
months 
None 11 3 12 4 17 1 4 3 12 36.0(24.5-79.0) 
N=24 Macronutrients 5 0 0 1 4 4 17 0 0 63.0(51.0-63.0 ) 
 Micronutrients+/- 
macronutrients 
8 0 0 0 0 5 21 3 12 82.0(57.0-128.5) 
18 
months 
None 12 3 17 7 39 2 11 0 0 32.0(21-46.5) 
N=18 Macronutrients 2 0 0 0 0 1 6 1 6 67.5(56.0- ) 
 Micronutrients+/- 
macronutrients
 ** 
3 0 0 0 0 3 17 0 0 64.0(42.7-134.0) 
24 
months 
None 5 1 8 2 17 2 17 0 0 45.0 (28.0-64.5) 
N=12 Macronutrients 0 0 0 0 0 0 0 0 0  
 Micronutrients+/- 
macronutrients 
7 2 17 1 8 0 0 4 33 67.0(23.7-106.2) 
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Supplementary material  
Supplemental table I. Prevalence of plasma 25(OH)D inadequacy of paediatric cancer patients 
with data stratified by diagnostic criteria. 
Figure legends 
Figure 1. Flow chart showing the sample size at different stages of the study period 
Figure 2. Plasma 25(OH)D with data stratified according to seasonal variation 
Error bars are standard deviations; *p<0.05, independent t-test used to compare 25(OH)D 
concentration between synthesising (1st of April-30th Sep) and non-synthesising periods (1st 
Oct-31st Mar).    
Figure 3. Plasma 25(OH)D concentration (left) and prevalence of 25(OH)D deficiency and 
insufficiency (right) at different stages of the study period.      
Error bars (left) are standard deviations. 
